142752-12-3

Basic information

• Product Name: 1-(4-aminophenyl)piperidin-4-ol
• Synonyms: 1-(4-aminophenyl)piperidin-4-ol;1-(4-AMINOPHENYL)-4-HYDROXYPIPERIDINE;OTAVA-BB 1147946
• CAS NO: 142752-12-3
• Molecular Formula: C₁₁H₁₆N₂O
• Molecular Weight: 192.26
• Mol File: 142752-12-3.mol
• Article Data: 18

Chemical Properties

• Melting Point: 158 °C
• Boiling Point: 404.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.194±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.88±0.20(Predicted)
• CAS DataBase Reference: 1-(4-aminophenyl)piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-aminophenyl)piperidin-4-ol(142752-12-3)
• EPA Substance Registry System: 1-(4-aminophenyl)piperidin-4-ol(142752-12-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 142752-12-3(Hazardous Substances Data)

Usage

General Description

1-(4-aminophenyl)piperidin-4-ol is a chemical compound that is a structural isomer of fentanyl, a powerful synthetic opioid analgesic used for severe pain management. Its complex structure includes a piperidinol functional group, which is derived from piperidine, and an aminophenyl group, which is derived from aniline. The presence of both hydroxyl and amine functional groups makes it potentially reactive; however, very little specific information is available regarding its physical properties, uses, or biological effects due to its specialized nature and limited applications in drug development or related fields. However, it is important to handle this chemical compound with caution due to its potential potency and reactivity.

Upstream product

• 79421-45-7 4-(4-hydroxypiperidinyl)nitrobenzene 
• 350-46-9 4-Fluoronitrobenzene 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 1244967-96-1 N-(4-(4-hydroxypiperidin-1-yl)-phenyl)-4-((1-methylpyrrol-2-yl)-carbonyl)-1-piperazinecarboxamide 
• 1415794-29-4 2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yloxy)ethanol 
• 1226154-84-2 1-(4-bromophenyl)piperidin-4-ol 
• 1415794-27-2 tert-butyl 2-(1-(4-bromophenyl)piperidin-4-yloxy)acetate 
• 1415794-28-3 2-(1-(4-bromophenyl)piperidin-4-yloxy)ethanol 
• 1127364-90-2 N-(4-(2-(4-(4-hydroxypiperidin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)methanesulfonamide 
• 1192708-56-7 1-(4-(4-(cyclobutylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperidin-4-ol 
• 1122710-01-3 1-(4-(4-(1H-indazol-6-ylamino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperidin-4-ol 
• 119836-12-3 4-hydroxy-1-(4-chlorophenyl)piperidine 
• 251369-96-7 1-Methyl-7-[4-(4-hydroxypiperidin-1-yl)phenylamino]-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2(1H)-one 
• 251371-45-6 1-Isopropyl-7-[4-(4-hydroxypiperidin-1-yl)phenylamino]-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2(1H)-one 

Relevant articles and documents

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor

Focal adhesion kinase (FAK) is a tyrosine kinase with prominent roles in protein scaffolding, migration, angiogenesis, and anchorage-independent cell survival and is an attractive target for the development of cancer therapeutics. However, current FAK inhibitors display dual kinase inhibition and/or significant activity on several kinases. Although multitargeted activity is at times therapeutically advantageous, such behavior can also lead to toxicity and confound chemical-biology studies. We report a novel series of small molecules based on a tricyclic pyrimidothiazolodiazepinone core that displays both high potency and selectivity for FAK. Structure-activity relationship (SAR) studies explored modifications to the thiazole, diazepinone, and aniline "tail,"which identified lead compound BJG-03-025. BJG-03-025 displays potent biochemical FAK inhibition (IC50 = 20 nM), excellent kinome selectivity, activity in 3D-culture breast and gastric cancer models, and favorable pharmacokinetic properties in mice. BJG-03-025 is a valuable chemical probe for evaluation of FAK-dependent biology.

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

To develop novel therapeutic agents with anticancer activities, two series of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivatives were designed and synthesized. All compounds were tested for anti-proliferative activities against five cancer cell lines. The structure-activity relationships (SARs) studies were conducted through the variation in two regions, the moiety of A ring and the terminal aniline B on pteridinone core. 1-Methyl-1,2,4-triazole derivative L7 with 2,6-dimethylpiperazine showed the most potent antiproliferative activity against A549, PC-3, HCT116, MCF-7 and MDA-MB-231 cell lines with IC50 values of 0.16 μM, 0.30 μM, 0.51 μM, 0.30 μM, and 0.70 μM, respectively. Combined with the results of the molecular docking and enzymatic studies, the PLK1 was very likely to be one of the drug targets of compound L7. Furthermore, to clarify the anticancer mechanism of compound L7, further explorations in the bioactivity were conducted. The results showed that compound L7 obviously inhibited proliferation of A549 cell lines, induced a great decrease in mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested G1 phase of A549 cells.